Financials in USD. Standardized financial statements.
A compact view of how Arbutus Biopharma Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M | $6.91M | $6.01M | $5.90M | $10.70M | $1.50M |
| Revenue Growth? | +128.2% | -66.0% | -53.5% | +255.1% | +58.9% | +15.0% | +1.9% | -44.9% | +613.3% | 0.0% |
| Cost of Revenue? | $363,000 | $0 | $0 | $0 | $0 | $47.48M | $57.60M | $57.90M | $62.70M | $61.30M |
| Gross Profit? | $13.72M | $6.17M | $18.14M | $39.02M | $10.99M | -$40.57M | -$51.59M | -$52.00M | -$52.00M | -$59.80M |
| Gross Margin? | +97.4% | +100.0% | +100.0% | +100.0% | +100.0% | -586.7% | -858.3% | -881.4% | -486.0% | -3986.7% |
| Operating Expenses? | $40.77M | $82.49M | $96.24M | $104.47M | $84.51M | $17.24M | $92.31M | $76.10M | $80.80M | $101.80M |
| Operating Income? | -$27.05M | -$76.32M | -$78.10M | -$65.46M | -$73.52M | -$57.81M | -$143.90M | -$89.80M | -$110.90M | -$491.60M |
| EBITDA? | -$26.69M | -$68.40M | -$70.99M | -$61.86M | -$71.64M | -$57.76M | -$162.24M | -$58.95M | -$106.44M | -$488.07M |
| Income Before Tax | -$33.50M | -$69.92M | -$72.85M | -$65.01M | -$76.25M | -$63.74M | -$166.38M | -$61.40M | -$108.70M | -$489.10M |
| Income Tax Expense | $0 | $0 | $0 | $4.44M | $0 | $0 | -$12.66M | -$4.30M | -$24.30M | -$105.00M |
| Net Income? | -$33.50M | -$69.92M | -$72.85M | -$69.46M | -$76.25M | -$63.74M | -$153.72M | -$57.10M | -$84.40M | -$384.10M |
| EPS? | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.73 | $-0.86 | $-2.69 | $-1.03 | $-1.54 | $-7.24 |
| Diluted EPS? | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.73 | $-0.86 | $-2.69 | $-1.03 | $-1.54 | $-7.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality